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Purpose: Implant survival is the most accepted measurement of total
knee (TKA) or hip arthroplasty (THA) results. There is a need for short-
term surrogates for revision for both research andmonitoring purposes.
We have shown that highest utilisation of non-steroidal anti-inﬂam-
matory drugs (NSAIDs) in the ﬁrst year following surgery is related to
increased revision risk, and hence a useful surrogate for “poor
outcome”. We therefore aimed to identify predictors of high NSAID use
at year 1 after TKA and THA surgery.
Methods: Study design and population: We used data from the
Catalan Joint Registry (RACAT), and linked it (85% linked) to comput-
erized primary care records and pharmacy invoice data (SIDIAP
Database). We identiﬁed patients aged >¼40 years undergoing
primary TKA/THA for osteoarthritis registered in the resulting dataset
in the period 1/1/2005-31/07/2012). We excluded patients receiving
revision surgery in the ﬁrst year post-surgery.Ă- Outcome assessment: NSAID utilisation was measured using
pharmacy invoice data, and quantiﬁed in number of Daily
Deﬁned Doses (DDDs) according to the WHO ATC/DDD index.
We classiﬁed patients in the top quintile (percentile 80 and
over) of utilisation as those with a “poor outcome”.
- Potential predictors: we deﬁned a priori a set of predictors of
poor outcome based on previous knowledge and biological
plausibility, including: age, sex, socio-economic status, Charl-
son co-morbidity index, alcohol drinking, smoking status, body
mass index, stroke/TIA, ischaemic heart disease, peripheral
artheriopathy, depression/anxiety disorders, type 2 diabetes
mellitus, previous fracture, chronic kidney failure, COPD, use of
atypical analgesics (gabapentin, pregabalin or trycyclic anti-
depressants) in the previous year, use of NSAIDs in the previous
year.
- Analysis: Backwards stepwise logistic regression (p-entry 0.05,
p-exit 0.1) models were ﬁtted to identify predictors of good
outcome (as deﬁned above).
Results: 22,221 and 10,173 patients undergoing TKA and THA for
osteoarthritis were included. Female sex, lower socio-economic
status, obesity, previous use of atypical analgesics, and amount of
NSAIDs used in the year prior to surgery were associated with “poor
outcome” in both THA and TKA patients [Figure, top and bottom
respectively]. Conversely, Charlson co-morbidity index had an effect
on poorer outcome for TKA patients, and a history of depression/
anxiety disorders was related to poorer outcome following THA, but
had no signiﬁcant effect on the other subpopulation.
Conclusions:We report for the ﬁrst time on a set of predictors of “poor
outcome” as deﬁned on the basis of NSAID usage during the ﬁrst year
following TKA surgery. A predictive tool can be built using these in order
to target patients who would beneﬁt the least from this surgical
procedure. A validated version of such tool would be of interest for
patients, clinicians and health-care managers.
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Purpose: Osteolysis and aseptic loosening are the most common cause
of revision arthroplasty worldwide. Bisphosphonates might improve
implant survival through their anti-osteoclast effects. We aimed to
study the association between bisphosphonate use and implant
survival.
Methods: A retrospective cohort study was conducted within the
Danish nationwide registries (5.5 million residents). We identiﬁed
patients aged >¼40 years undergoing total joint replacement (TJR)
during the study period (1998-2007) using ICD10 codes. Patients with
inﬂammatory arthritides, bone Paget, hip fracture and use of DMARDs
were excluded. Each participant was followed up until end of study,
date of emigration, revision surgery, or patient's death, whichever came
ﬁrst. Participants were classiﬁed as bisphosphonate users (BPU) if they
had been on treatment for at least 6 months. A time-varying exposure
was used to avoid immortal-time bias. Up to six BP non-users (BPNU)
undergoing arthroplasty were matched to each BPU using propensity
scores. Stratiﬁed Cox regression was used to model implant survival
according to bisphosphonate use. Further, we studied the association
between duration of use, adherence (medication possession
ratio¼MPR), and timing of therapy initiation (pre-op vs post-op) and
implant survival. Finally, we tested for a-priori deﬁned interactions
